Preclinical compounds for the treatment of overactive bladder.
BACKGROUND
Overactive bladder is a prevalent and bothersome condition. Existing pharmacotherapy with antimuscarinics improves symptoms and quality of life but there are certain limitations in efficacy and tolerability.


OBJECTIVE
To review novel, recently patented compounds for the treatment of overactive bladder.


METHODS
The European Patent Office database was searched for compounds that emerged in the last 3 years.


CONCLUSIONS
Overactive bladder pathophysiology and treatment is an active field of research. Molecules that modulate/inhibit afferent nerve pathways are the focus of interest and the most promising field of overactive bladder drug development.
Urology Department, Urology Patras University General Hospital, Rion, Patras, Greece.
Konstantinos
K
Giannitsas
Angelis
A
Konstantinopoulos
Christos
C
Patsialas
Anastasios
A
Athanasopoulos
Petros
P
Perimenis
D000344:Afferent Pathways / Q000187:drug effects* / Q000378:metabolism; D000818:Animals; D004353:Drug Evaluation, Preclinical; D006801:Humans; D018727:Muscarinic Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D010330:Patents as Topic; D011788:Quality of Life; D053201:Urinary Bladder, Overactive / Q000188:drug therapy* / Q000503:physiopathology
D018727:Muscarinic Antagonists